Pharming Group N.V. (PHGUF)

Market Cap	1.08B +83.6%
Revenue (ttm)	362.27M +26.8%
Net Income	382.00K
EPS	0.00
Shares Out	n/a
PE Ratio	2,824.02
Forward PE	34.41
Dividend	n/a
Ex-Dividend Date	n/a

Volume	5,590
Average Volume	2,661
Open	2.170
Previous Close	1.850
Day's Range	2.150 - 2.170
52-Week Range	0.790 - 2.170
Beta	0.23
RSI	79.45
Earnings Date	Mar 12, 2026

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company’s lead product is RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3Kẟ inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome. It also dev...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 1988
• Employees: 404
• Stock Exchange: OTCMKTS
• Ticker Symbol: PHGUF

Financial Performance

In 2024, Pharming Group's revenue was $297.20 million, an increase of 21.15% compared to the previous year's $245.32 million. Losses were -$11.84 million, 12.3% more than in 2023.